Oxurion Competitors and Similar CompaniesClear all
Aerie Pharmaceuticals's competitors and similar companies include Alnylam and Catalyst Pharmaceuticals.
 Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. | |
Founding Date | Founding Date 2005 | Founding Date 2002 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Irvine, US HQ Dublin, IE 千代田区, JP Henley On Thames, GB Bedminster, US Durham, US | Locations Coral Gables, US HQ | |
Employees | Employees 3808% increase | Employees 1,32324% increase | Employees 7649% increase |
Valuation ($) | Valuation ($) 722.2 m | Valuation ($) 36.5 b | Valuation ($) 2.6 b |
Financial | |||
Revenue (est.) | Revenue (est.) $194.1m (FY, 2021) | Revenue (est.) $3.7b (FY, 2025) | Revenue (est.) $589m (FY, 2025) |
Cost of goods | Cost of goods $26.8m (FY, 2021) | Cost of goods $677.2m (FY, 2025) | Cost of goods $87.3m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $3b (FY, 2025) | Gross profit $501.7m (FY, 2025) |
Net income | Net income ($74.8m) (FY, 2021) | Net income $313.7m (FY, 2025) | Net income $214.3m (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised $ 388.6m | Total funding raised $ 1.5b | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Alnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View companyCatalyst Pharmaceuticals
HQ
Coral Gables, US
Employees
76↑ 49% increase
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.
View company